FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284964301> ?p ?o ?g. }

• W4284964301 abstract "Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be responsible for a heavy burden, inducing pain, aesthetic prejudice, or oozing, bleeding, infections. The natural history of LMLMs is progressive worsening punctuated by acute flares. Therapeutic options include surgery, laser excision, and radiofrequency ablation but all are potentially detrimental and expose to local relapse. Therefore, the management frequently relies on a watchful waiting approach. In complicated LMLMs, treatment with oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is often used. Topical applications of sirolimus on the buccal mucosae have been reported in other oral diseases with good tolerance and none to slight detectable blood sirolimus concentrations. We aim to evaluate the efficacy and safety of a 1 mg/mL sirolimus solution applied once daily on LMLM of any stage in children and adults after 4, 8, 12, 16, 20, and 24 weeks of treatment compared to usual care (no treatment).This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus usual care (no treatment), the control condition. Participants begin with an observational period and later switch to the intervention at a randomized time (week 0, 4, 8, or 12). Visits occur every 4 weeks, either in the study center or by teleconsulting. The primary outcome will be the evaluation of global severity of the LMLM on monthly standardized photographs by 3 independent blinded experts using the physical global assessment (PGA) 0 to 5 scale. Secondary outcomes will include lesion size measurement and quality of life assessment, investigator, and patient-assessed global disease and specific symptoms (oozing, bleeding, sialorrhea, eating impairment, taste modification, aesthetic impairment, pain, and global discomfort) assessment. A biological monitoring will be performed including residual blood sirolimus concentration and usual laboratory parameters.Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated.ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorities: ID RCB: 2019-001530-33." @default.
• W4284964301 created "2022-07-10" @default.
• W4284964301 creator A5001564881 @default.
• W4284964301 creator A5002485469 @default.
• W4284964301 creator A5014276587 @default.
• W4284964301 creator A5017659011 @default.
• W4284964301 creator A5024960922 @default.
• W4284964301 creator A5080070625 @default.
• W4284964301 creator A5080253786 @default.
• W4284964301 creator A5080398125 @default.
• W4284964301 creator A5090924104 @default.
• W4284964301 date "2022-07-08" @default.
• W4284964301 modified "2023-10-18" @default.
• W4284964301 title "Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial" @default.
• W4284964301 cites W1591725541 @default.
• W4284964301 cites W1706136667 @default.
• W4284964301 cites W1990099588 @default.
• W4284964301 cites W2000239178 @default.
• W4284964301 cites W2008416056 @default.
• W4284964301 cites W2013884649 @default.
• W4284964301 cites W2017426694 @default.
• W4284964301 cites W2022137053 @default.
• W4284964301 cites W2046980755 @default.
• W4284964301 cites W2049852556 @default.
• W4284964301 cites W2055760063 @default.
• W4284964301 cites W2057600556 @default.
• W4284964301 cites W2058227241 @default.
• W4284964301 cites W2059661118 @default.
• W4284964301 cites W2085928717 @default.
• W4284964301 cites W2087522639 @default.
• W4284964301 cites W2089354038 @default.
• W4284964301 cites W2107799646 @default.
• W4284964301 cites W2109616095 @default.
• W4284964301 cites W2110109000 @default.
• W4284964301 cites W2132547376 @default.
• W4284964301 cites W2145682933 @default.
• W4284964301 cites W2148072374 @default.
• W4284964301 cites W2166023752 @default.
• W4284964301 cites W2168139530 @default.
• W4284964301 cites W2270054557 @default.
• W4284964301 cites W2282181553 @default.
• W4284964301 cites W2320404255 @default.
• W4284964301 cites W2392938395 @default.
• W4284964301 cites W2416901675 @default.
• W4284964301 cites W2542703599 @default.
• W4284964301 cites W2605881496 @default.
• W4284964301 cites W2613422131 @default.
• W4284964301 cites W2768767480 @default.
• W4284964301 cites W2809688907 @default.
• W4284964301 cites W2891102352 @default.
• W4284964301 cites W2914050470 @default.
• W4284964301 cites W2941252208 @default.
• W4284964301 cites W2995369961 @default.
• W4284964301 doi "https://doi.org/10.1186/s13063-022-06365-y" @default.
• W4284964301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35804404" @default.
• W4284964301 hasPublicationYear "2022" @default.
• W4284964301 type Work @default.
• W4284964301 citedByCount "1" @default.
• W4284964301 countsByYear W42849643012023 @default.
• W4284964301 crossrefType "journal-article" @default.
• W4284964301 hasAuthorship W4284964301A5001564881 @default.
• W4284964301 hasAuthorship W4284964301A5002485469 @default.
• W4284964301 hasAuthorship W4284964301A5014276587 @default.
• W4284964301 hasAuthorship W4284964301A5017659011 @default.
• W4284964301 hasAuthorship W4284964301A5024960922 @default.
• W4284964301 hasAuthorship W4284964301A5080070625 @default.
• W4284964301 hasAuthorship W4284964301A5080253786 @default.
• W4284964301 hasAuthorship W4284964301A5080398125 @default.
• W4284964301 hasAuthorship W4284964301A5090924104 @default.
• W4284964301 hasBestOaLocation W42849643011 @default.
• W4284964301 hasConcept C126322002 @default.
• W4284964301 hasConcept C141071460 @default.
• W4284964301 hasConcept C168563851 @default.
• W4284964301 hasConcept C23131810 @default.
• W4284964301 hasConcept C2777921159 @default.
• W4284964301 hasConcept C535046627 @default.
• W4284964301 hasConcept C71924100 @default.
• W4284964301 hasConceptScore W4284964301C126322002 @default.
• W4284964301 hasConceptScore W4284964301C141071460 @default.
• W4284964301 hasConceptScore W4284964301C168563851 @default.
• W4284964301 hasConceptScore W4284964301C23131810 @default.
• W4284964301 hasConceptScore W4284964301C2777921159 @default.
• W4284964301 hasConceptScore W4284964301C535046627 @default.
• W4284964301 hasConceptScore W4284964301C71924100 @default.
• W4284964301 hasIssue "1" @default.
• W4284964301 hasLocation W42849643011 @default.
• W4284964301 hasLocation W42849643012 @default.
• W4284964301 hasLocation W42849643013 @default.
• W4284964301 hasLocation W42849643014 @default.
• W4284964301 hasLocation W42849643015 @default.
• W4284964301 hasOpenAccess W4284964301 @default.
• W4284964301 hasPrimaryLocation W42849643011 @default.
• W4284964301 hasRelatedWork W1586374228 @default.
• W4284964301 hasRelatedWork W1967947002 @default.
• W4284964301 hasRelatedWork W2003938723 @default.
• W4284964301 hasRelatedWork W2047967234 @default.
• W4284964301 hasRelatedWork W2118496982 @default.
• W4284964301 hasRelatedWork W2364998975 @default.
• W4284964301 hasRelatedWork W2369162477 @default.
• W4284964301 hasRelatedWork W2439875401 @default.

• next